rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiset aineet - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
erlotinib stada 25 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - erlotinib hydrochloride - tabletti, kalvopäällysteinen - 25 mg - erlotinibi
erlotinib stada 100 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - erlotinib hydrochloride - tabletti, kalvopäällysteinen - 100 mg - erlotinibi
erlotinib stada 150 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - erlotinib hydrochloride - tabletti, kalvopäällysteinen - 150 mg - erlotinibi
erlotinib orion 25 mg tabletti, kalvopäällysteinen
orion corporation - erlotinib hydrochloride - tabletti, kalvopäällysteinen - 25 mg - erlotinibi
erlotinib orion 100 mg tabletti, kalvopäällysteinen
orion corporation - erlotinib hydrochloride - tabletti, kalvopäällysteinen - 100 mg - erlotinibi
erlotinib orion 150 mg tabletti, kalvopäällysteinen
orion corporation - erlotinib hydrochloride - tabletti, kalvopäällysteinen - 150 mg - erlotinibi
erlotinib avansor 25 mg tabletti, kalvopäällysteinen
avansor pharma oy - erlotinib hydrochloride - tabletti, kalvopäällysteinen - 25 mg - erlotinibi
erlotinib avansor 100 mg tabletti, kalvopäällysteinen
avansor pharma oy - erlotinib hydrochloride - tabletti, kalvopäällysteinen - 100 mg - erlotinibi
erlotinib avansor 150 mg tabletti, kalvopäällysteinen
avansor pharma oy - erlotinib hydrochloride - tabletti, kalvopäällysteinen - 150 mg - erlotinibi